Texas HB 46 ten months in: license rollout on track, patient enrollment trailing the headlines

In June 2025, Governor Greg Abbott signed House Bill 46, the largest single-bill expansion of the Texas Compassionate Use Program (TCUP) since the program was created in 2015. The bill added three qualifying conditions (chronic pain, Crohn's disease, traumatic brain injury), authorized new product forms (lotions, patches, suppositories, vaporized products), and required the Department of Public Safety to issue 12 additional dispensary licenses to grow the program from its long-standing 3-operator footprint to a target of 15 statewide operators.

Ten months later, the regulatory rollout is largely on schedule. DPS issued nine new licenses by December 2025, with the remaining three expected by April 2026. Several of the new operators have begun build-out at conditional license stages. Patient enrollment has grown but at a pace below what the bill's proponents projected. The structural ceiling of the program (1% THC cap, no smokable flower, no home cultivation, no insurance coverage, no reciprocity) remains the operative constraint.

This article maps what has actually happened in the ten months since HB 46 became law, what hasn't, and what the next eighteen months look like for Texas patients.

What HB 46 changed, in operational terms

The HB 46 expansion sits on top of TCUP's existing framework codified at Texas Health & Safety Code Chapter 487, with the program administered jointly by the Department of Public Safety (operator licensing) and the Texas Medical Board (physician registration).

The 2025 statutory additions:

• New qualifying conditions:
  • Chronic pain (continuous or intermittent severe pain for more than 90 days), expanding TCUP into the single condition that dominates qualifying-patient populations nationally.
  • Crohn's disease, joining the inflammatory-bowel-disease category.
  • Traumatic brain injury, with established VA-research support for cannabinoid intervention.
  • Terminal illness / hospice status, providing a fast-track qualification for late-stage patients.
• New product forms: lotions, patches, suppositories, and (most consequentially) non-smoked pulmonary inhalation — i.e., vaporization of authorized cannabis preparations.
• License expansion: statutory mandate of 15 total dispensing-organization licenses, requiring DPS to issue 12 additional licenses against the existing 3-operator baseline.
• Operational requirements: new operators must become operational within 24 months of license issuance; providers may open satellite brick-and-mortar dispensaries; patient data integrated into the Texas Board of Pharmacy's Prescription Monitoring Program.

What HB 46 left unchanged is more consequential than what it changed:

• 1% THC cap by weight (raised from 0.5% to 1% in 2021, unchanged in 2025).
• No smokable flower.
• No home cultivation.
• No reciprocity for out-of-state medical cards.
• No insurance coverage at state-program level.
• No employment-discrimination protections.

The combination produces a program structurally distinct from comprehensive medical states. TCUP is a prescription pathway for specific cannabinoid products in specific delivery forms, not a "medical cannabis" framework as Florida, Pennsylvania, or Ohio define it.

The licensing rollout: ahead of schedule

The DPS licensing pipeline has performed roughly as the statute required. The agency issued nine conditional licenses by December 2025 — a tranche that included multiple Houston-region operators (per Houston Public Media reporting) and additional operators in DFW, Austin/Hill Country, and South Texas regions. The remaining three licenses are scheduled for issuance by April 2026.

What "conditional license" means in TCUP practice: the operator must complete facility construction, pass state inspection, and demonstrate compliance with security, cultivation, and processing standards before the conditional license converts to operational. The statutory 24-month operational window gives new licensees until late 2027 (for the December 2025 tranche) and early 2028 (for the April 2026 tranche) to reach revenue stage.

For a Texas patient with a qualifying condition, this means:

• Existing patients have access through the three operational TCUP operators that have served the program since 2018–2020.
• New patients in newly-licensed-but-not-yet-operational regions will see access expand on a rolling basis through 2027.
• The full 15-operator footprint, with satellite dispensaries fanning out from each parent license, is unlikely to be fully built out before 2028.

The enrollment trajectory

TCUP's pre-HB 46 patient population sat in the low five figures — a small fraction of what a state with Texas's population would generate under a comprehensive medical framework. HB 46's three new conditions (chronic pain especially) opened the program to a substantially larger eligible population.

The enrollment growth has been real but constrained. Chronic pain is the most-cited qualifying condition in any state that authorizes it as a standalone diagnosis. A conservative estimate of Texas adults with chronic pain meeting TCUP's "continuous or intermittent severe pain for more than 90 days" definition puts the eligible population in the hundreds of thousands. Actual TCUP enrollment under the expanded condition list, ten months in, has grown into the five figures but has not approached six figures.

Why the gap between eligible and enrolled? Three structural reasons:

1. The 1% THC cap. A patient with severe chronic pain who consumes cannabis recreationally in a neighboring state, or who has access to hemp-derived Delta-9 / Delta-8 products under Texas's separate hemp framework, faces a clear product-quality calculation. TCUP's authorized products are lower-potency than what is available in less-restrictive channels.
2. The prescribing physician bottleneck. TCUP requires registration through the Texas Medical Board's Compassionate Use Registry. The registered-physician roster has grown but remains a fraction of Texas's total practicing physician population, particularly in rural areas.
3. The hemp-market competition. Texas's 2019 hemp framework authorized retail sale of hemp-derived cannabinoid products (Delta-8 THC, Delta-9 THC at federally compliant concentrations, THCA flower). For a Texas resident seeking cannabinoid-mediated symptom relief without medical-program registration, the hemp retail option has been the path of least resistance.

The HB 46 expansion was a deliberate consolidation move: pull legitimate medical demand into a regulated channel, push the hemp-derived market into a more constrained regulatory posture. The March 2026 hemp-products rollback (with subsequent April 2026 court injunction) is the parallel front in that consolidation. Whether it succeeds depends on outcomes that are still being litigated.

What HB 46 did not do, that the legislature could revisit

The 2027 Texas legislative session will face renewed pressure on the structural ceilings HB 46 left in place. The three most-discussed potential 2027 reforms:

• THC cap adjustment. Raising the 1% cap to a higher threshold (5%, 10%, or removing it entirely for specific product forms) would meaningfully change the available product spectrum and reduce the hemp-market migration. The legislative posture has historically been hostile, but the HB 46 vote demonstrated that incremental expansion is politically viable.
• Smokable flower authorization. This is the most politically charged remaining reform. Smokable cannabis remains the most-consumed cannabis product form nationally, and TCUP's exclusion of flower is the single largest structural difference between TCUP and a comprehensive medical program. The 2025 hemp legislation that banned smokable hemp flower suggests the legislature is not currently inclined to authorize smokable medical cannabis either.
• Reciprocity for out-of-state medical cards. A reciprocity provision would allow visiting patients from Oklahoma, New Mexico, Arkansas, Louisiana, and other neighboring states to legally purchase TCUP product. The tax-revenue case is strong; the political case has not yet been made.

The PMP integration and what it signals

One of the less-discussed but operationally consequential HB 46 provisions is the integration of TCUP-dispensed cannabis into the Texas Prescription Monitoring Program administered by the Texas Board of Pharmacy. Pre-HB 46, TCUP product dispensations were tracked in the Compassionate Use Registry maintained by the Department of Public Safety but did not flow into the broader controlled-substance monitoring infrastructure that physicians use to evaluate opioid and benzodiazepine prescribing.

Post-HB 46, dispensations are monitored by the Board of Pharmacy through PMP. Patient identification information in the registry is confidential and may only be accessed by:

• The Department of Public Safety (program-administration purposes).
• Registered physicians and dispensing organizations (for patient-care purposes).
• The Texas Board of Pharmacy (controlled-substance-monitoring purposes).

The integration has two implications:

1. TCUP looks more like prescription medicine and less like a parallel medical-cannabis program. PMP integration aligns TCUP's clinical workflow with how other controlled-substance prescribing is monitored. For physicians who already check PMP before prescribing opioids, the TCUP integration reduces the procedural distance between cannabis certification and conventional pain-management prescribing.
2. The patient-privacy implications are real. PMP integration means TCUP participation is visible to a broader set of healthcare practitioners and to state regulators in ways the older Compassionate Use Registry was not. For patients in employment contexts where any controlled-substance prescription history might be relevant (federally regulated transportation, security-clearance review), this is a meaningful change to consider.

What HB 46 means for the chronic-pain population specifically

The single largest population shift HB 46 produced is the inclusion of chronic-pain patients in TCUP. The statutory definition ("continuous or intermittent severe pain for more than 90 days") is broad enough to capture a substantial share of the Texas adult population currently managing chronic pain through opioids, NSAIDs, physical therapy, interventional procedures, or some combination.

For Texas chronic-pain physicians and pain-medicine specialists, HB 46 created a new clinical-practice consideration: whether and when to add TCUP cannabis to a multi-modal pain-management plan. The clinical evidence is supportive in the population sense — NASEM's 2017 systematic review identified "substantial evidence" that cannabis is effective for chronic-pain management in adults — but is less specific about which chronic-pain phenotypes (neuropathic, nociceptive, mixed), which patients (opioid-naive vs. opioid-tolerant), and which products (which cannabinoid ratios, which delivery routes) produce the best outcomes.

Texas physicians who have begun integrating TCUP into chronic-pain workflows report a similar pattern to early-program adopters in Pennsylvania and Maryland:

• The chronic-pain certifications are heavily weighted toward neuropathic and post-surgical pain populations.
• Combination therapy (cannabis added to existing opioid regimens, often with intent to reduce opioid dose) is more common than cannabis as primary monotherapy.
• The 1% THC cap limits product selection in ways that constrain the matching of product to specific pain phenotype.

For chronic-pain patients in particular, HB 46 is most valuable as a legal-access pathway to cannabinoid-based therapy adjuncts. It is less effective as a comprehensive cannabis-product-selection framework, given the THC cap.

How HB 46 compares regionally

Texas's program, post-HB 46, is now meaningfully broader than several neighbors but still narrower than the regional comprehensive programs:

• Oklahoma (comprehensive medical, very high patient penetration): substantially broader than Texas across every dimension.
• New Mexico (comprehensive medical + full adult-use since 2022): substantially broader than Texas.
• Louisiana (comprehensive medical): broader than Texas on product forms and condition list.
• Arkansas (comprehensive medical): broader than Texas on product forms.
• Mississippi (comprehensive medical at 60,000+ patients): broader than Texas.

A Texas chronic-pain patient now has a legal in-state pathway. The same patient with a preference for higher-potency or smokable products has the same incentive structure as before HB 46: cross a state line or use the hemp market.

What to watch through the rest of 2026

Three operational milestones will shape the program through year-end:

1. DPS completion of remaining license issuance by April 2026. On track per current DPS statements.
2. First operational openings from the December 2025 license tranche. The 24-month operational window means earliest openings could occur in late 2026, with most new operators reaching revenue stage in 2027.
3. Texas Supreme Court resolution of the hemp injunction. The April 8, 2026 injunction that lifted the smokable-hemp ban is on appellate review. A reversal would push more hemp-using Texans toward TCUP enrollment. An affirmation would entrench the hemp market and leave TCUP enrollment growth structurally capped.

HB 46 was the most ambitious TCUP expansion in a decade. Its operational rollout is performing roughly as designed. Its structural ceiling has not changed, and the next reform window opens with the 2027 legislative session.

[Last reviewed 2026-05-18. This is informational only — not medical or legal advice.]